Joslin Diabetes Center

L-Nutra Health® Pioneers New, Innovative Therapeutic Healthcare Model with Official Diabetes Patent

Retrieved on: 
Tuesday, March 19, 2024
Stem cell, Glucose, Facial muscles, Longevity, Regeneration, FMD, Health, Diabetes, Patient, Harvard University, Weight loss, Hope, Joslin Diabetes Center, Insulin resistance, Patent, Physician, Ageing, Pharmaceutical industry

With this historic achievement in nutrition-led healthcare, L-Nutra Health® solidifies its position as the authoritative leader in science-backed nutrition technology.

Key Points: 
  • With this historic achievement in nutrition-led healthcare, L-Nutra Health® solidifies its position as the authoritative leader in science-backed nutrition technology.
  • The comprehensive program includes supervision by lifestyle medicine physicians and personalized support from dietitians uniquely trained in longevity and diabetes.
  • Through nutrition, L-Nutra Health® is redefining the landscape of type 2 diabetes management and the speed of regression.
  • "This patent stands as a testament to our steadfast commitment to providing pioneering solutions that define a new therapeutic category, positioning L-Nutra Health® at the forefront of healthcare."

L-Nutra Unveils Groundbreaking Research on Fasting Mimicking Diets (FMDs) and Reduced Biological Age Score

Retrieved on: 
Wednesday, February 28, 2024
Nature, The, NHANES, Ageing, Health, Food, Harvard University, Joslin Diabetes Center, University of Southern California, FMD, Longevity, Facial muscles, University, Fasting, Yale University, Nature Communications, Life, Research, Medicine, Dietary supplement

LOS ANGELES, Feb. 28, 2024 /PRNewswire/ -- L-Nutra Inc., a leading nutrition technology company developing evidence-based Nutrition for Longevity and Nutrition as Medicine programs, is excited to announce the release of a groundbreaking longevity and healthy aging study published in Nature Communications, a prestigious Nature portfolio journal. The data suggests that following three consecutive monthly rounds of ProLon® 5-Day may decrease a person's biological age score by 2.5 years. 

Key Points: 
  • The data suggests that following three consecutive monthly rounds of ProLon® 5-Day may decrease a person's biological age score by 2.5 years.
  • L-Nutra's flagship product, ProLon® 5-day Fasting Mimicking Diet (FMD), the first patented precision nutrition program shown to support cellular rejuvenation and metabolic reset effects of prolonged fasting, was provided to participants.
  • This research further solidifies L-Nutra's commitment to advancing scientific understanding and practical applications of nutrition for living longer and healthier.
  • This study marks a significant step forward in understanding the effect of fasting-mimicking diets (FMD) in cellular rejuvenation, metabolic reset, and supporting healthy living.

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Retrieved on: 
Thursday, February 15, 2024
Diabetes, Senior, Pediatrics, MannKind Corporation, Joslin Diabetes Center, Safety, Adolescence, MDI, Young adult, Patient, Fasting, Insulin, MPH, Plasma, Harvard Medical School, Ageing, Pharmaceutical industry

Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.

Key Points: 
  • Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.
  • The multi-center study evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.
  • “We are excited to reach this milestone in exploring the potential of Afrezza for a younger generation living with diabetes,” said Dr. Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation.
  • “We expect to complete a primary endpoint analysis in the fourth quarter.”
    More information on the study details is available at: https://www.clinicaltrials.gov/study/NCT04974528

JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease Clinical Trial, Joins The Kidney Foundation of Canada in Driving Research to Treat Kidney Disease

Retrieved on: 
Monday, January 22, 2024
Diabetes, Patient, Research, Diabetic nephropathy, Kidney, Kidney failure, Person, T1D, CIHR, SGLT2, Team, University, Kidney disease, Joslin Diabetes Center, Risk, KFOC, Type 2 diabetes, Safety, Public, University of Toronto, SGLT, JDRF, Clinical trial, University Health Network, Pharmaceutical industry

Kidney disease remains a life-threatening complication for those living with diabetes.

Key Points: 
  • Kidney disease remains a life-threatening complication for those living with diabetes.
  • Almost half of kidney failure cases are caused by diabetes, and an estimated one out of three people with T1D develop significant kidney disease.
  • SUGARNSALT is one of the largest T1D focused kidney disease studies in the world, and it is the only phase 3 clinical trial targeting major kidney disease outcomes.
  • "The Kidney Foundation of Canada is proud to be one of the founding partners on this significant investment to support innovative strategies to treat diabetic kidney disease.

The American Diabetes Association Welcomes 2024 Principal Officers and Members to the National Board of Directors

Retrieved on: 
Wednesday, January 3, 2024
UCLA, Medicine, University, Pennsylvania State University, Bajaj, Public, Harvard University, Medicaid, Informatics, Johns Hopkins, Metabolism, Economics, Treatment, Medical Center, Luke the Evangelist, Conditional sentence, MBA, Harvard Business School, Urbański, Oregon State University, Doctor of Pharmacy, Anderson School of Management, Moda, Black, Medication, Baylor University, Bachelor of Science, Integrated delivery system, Division, Oklahoma State University–Stillwater, Kalyani, Education, Lee Ritenour, Medicare, Washington State University, Pharmacist, Committee on Finance, Cherokee Nation, Bon Secours Health System, Joslin Diabetes Center, Adventure, Management

ARLINGTON, Va., Jan. 3, 2024 /PRNewswire/ -- The American Diabetes Association® (ADA) welcomes the 2024 principal officers and board of directors.

Key Points: 
  • ARLINGTON, Va., Jan. 3, 2024 /PRNewswire/ -- The American Diabetes Association® (ADA) welcomes the 2024 principal officers and board of directors.
  • "We are so excited to announce our 2024 board of directors," said Charles "Chuck" Henderson, the ADA's chief executive officer.
  • We also want to thank our outgoing board members, Otis W. Kirksey, PharmD, RPh, CDCES, BC-ADM and Marshall Case.
  • We are very appreciative of their hard work, dedication, and commitment to fighting for all people affected by diabetes."

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

Retrieved on: 
Saturday, December 9, 2023
Phase, Flexner Report, Diabetes, Conference, BID, QD, Menin, ATTD, Animal, Week, DSM-IV codes, Cancer, Food, SAD, Gene, Patient, Diagnosis, Safety, Harvard Medical School, Joslin Diabetes Center, Osteopathic medicine in Canada, Kinetics, Pharmaceutical industry

At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.

Key Points: 
  • At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.
  • As presented at the conference, we have shown for the first time the long-term follow-up data of our 100 mg patient cohorts.
  • By increasing the dose from 100 mg to 200 mg, we are excited about nearly doubling the percentage of patients treated with BMF-219 having a robust HbA1c reduction of 1% or more, 22 weeks after the last dose.
  • Phase II consists of multiple ascending dose (MAD) cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

Retrieved on: 
Tuesday, November 14, 2023
Chronic kidney disease, Research, Telephone, Joslin Diabetes Center, Senior, GMT, Kidney disease, PIN, American Diabetes Association, Insurance, Patient, LSE, Calendar, FDA, Type 2 diabetes, PPO, Marketing, CMS, EGFR, Biomarker, Hospital, A1C, Physician, Diabetes, Patent, Medical device, Pharmaceutical industry, Health insurance, Cryptocurrency

During the three months ended September 30, 2023, the Company recognized $0.5 million of revenue, compared to $1.0 million for the three months ended September 30, 2022.

Key Points: 
  • During the three months ended September 30, 2023, the Company recognized $0.5 million of revenue, compared to $1.0 million for the three months ended September 30, 2022.
  • Cost of revenue for the three months ended September 30, 2023 was $0.5 million, compared to $0.7 million for the three months ended September 30, 2022.
  • Operating expenses for the three months ended September 30, 2023 was $8.8 million, compared to $12.0 million for the three months ended September 30, 2022.
  • Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

Retrieved on: 
Friday, October 6, 2023
Patent, Type 2 diabetes, Joslin Diabetes Center, Biomarker, Food, Risk, Insurance, SALT, Artificial intelligence, FDA, LSE, Kidney disease, Research, United States patent law, Pharmaceutical industry

These claims were filed under US Patent Application No.

Key Points: 
  • These claims were filed under US Patent Application No.
  • 16/671.256 by the Joslin Diabetes Center and this patent is exclusively licensed to Renalytix.
  • KidneyintelX.dkd received Food and Drug Administration de Novo marketing authorization on June 29, 2023.
  • A similar strategy to protect Renalytix’s intellectual property is being pursued in Europe, which also presents a large opportunity for KidneyIntelX expansion.

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Linda, Partnership, University, Pediatrics, Therapy, NOD, Outcomes research, Pediatric endocrinology, Immune tolerance, Pancreas, University of California, Research, Multiple sclerosis, Inflammation, Autoimmunity, Assistant, TCR, Harvard Medical School, ITN, Behavior, Indiana University School of Medicine, Patient, Division, Lymph, Insulitis, Benaroya Research Institute, Endocrinology, Biology, Joslin Diabetes Center, Pharmaceutical industry, Nursing, T1D, Regulatory T cell, Medicine

“We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.

Key Points: 
  • “We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.
  • Additional non-clinical studies have established the role of Tregs in suppressing β-cell injury, a further potential benefit of the approach.
  • “This second program expands the scope of our pioneering Treg cell-based approach to patients with T1D.
  • This group brings deep expertise in T1D pathogenesis and the clinical development of novel therapeutics.

Stefany Shaheen Co-Founder of Good Measures Appointed to President’s Council on Sports, Fitness & Nutrition

Retrieved on: 
Wednesday, June 28, 2023
General Health, Health, Fitness & Nutrition, Health Technology, Health Insurance, Exercise, Food, The New York Times, President's Council on Sports, Fitness, and Nutrition, Eating, Multimedia, Won Ton Ton, the Dog Who Saved Hollywood, Measure, Trustee, Council, Physical fitness, Fitness, Joslin Diabetes Center, Mental health, Diabetes, Pharmaceutical industry, Sport

Good Measures , a technology and health services and solutions company, celebrates yesterday’s swearing in of founder, Stefany Shaheen, to the President’s Council on Sports, Fitness & Nutrition.

Key Points: 
  • Good Measures , a technology and health services and solutions company, celebrates yesterday’s swearing in of founder, Stefany Shaheen, to the President’s Council on Sports, Fitness & Nutrition.
  • View the full release here: https://www.businesswire.com/news/home/20230628805359/en/
    Good Measures founder, Stefany Shaheen (bottom row, second from left, between co-chair José Andrés and Dr. Dariush Mozaffarian), attended the annual meeting of the President's Council on Sports, Fitness & Nutrition held on June 27, 2023.
  • Shaheen was sworn in as a new member of the Council.
  • The esteemed Council will also focus on expanding national awareness of the importance of mental health as it pertains to physical fitness and nutrition.